Background: Bronchial hyper-responsiveness (BHR) and variation in Glutathione Stransferase (GST) genes have been associated with asthma risk. We investigated the relationship of these two risk factors on adult onset asthma in the general population. Methods: GSTP1 Ile105Val single nucleotide polymorphism and GSTM1 and GSTT1 gene deletion polymorphisms were genotyped in the population-representative SAPALDIA cohort. BHR was assessed at baseline by methacholine challenge and defined as a
Introduction
Bronchial hyperresponsiveness (BHR) has been recognized as key feature of asthma, [1] a complex respiratory disorder characterized by chronic airway inflammation, increased mucus formation, airway wall thickening, and airway smooth muscle dysfunction. BHR often precedes the development of asthma, [2] [3] [4] but not all subjects exhibiting BHR will develop complete expression of asthma. [5] Genetic and environmental co-factors may promote or in contrast prevent the development of clinically relevant asthma phenotypes among subjects with BHR. According to experiments in mice both, airway inflammation and remodeling appear to contribute to development, progression, and persistence of BHR. [6] Thus genes expressed in bronchial tissue and involved in the modulation of inflammation and associated oxidative stress represent valid candidate genes likely to play a role as modifiers of asthma development among subjects with BHR.
Glutathione S-transferases (GSTs) are one group of candidate genes. GSTs are phase II detoxification enzymes involved in the clearing of tobacco smoke derived and other toxicants. [7] In addition, they have anti-oxidative capacities and can affect the systemic and local oxidative stress levels. [8] GSTP1 is the GST gene most abundantly expressed in the lungs. [9] Other highly prevalent GST variants are the homozygous gene deletions of GSTM1 and GSTT1, which were associated with lung function in the general population [10] [11] [12] and with respiratory disease. [13, 14] We have previously reported that baseline BHR, including silent BHR (i.e. BHR without concurrent report of respiratory symptoms), increases the likelihood of an incident asthma diagnosis within 11-years of follow-up in the population-based adult SAPALDIA cohort. [3] We now investigate whether genetic variation in GSTP1, GSTM1, and GSTT1 modifies the association of BHR with the development of asthma. In particular, a GSTP1 Ile/Val single nucleotide polymorphism at the amino acid residue 105 results in different enzymatic efficiency. [15] GSTP1 105Val hetero-or homozygous carriers have been shown to experience a protective effect against asthma [16] and atopic airway inflammation. [17] We therefore hypothesized that the risk increasing effect of BHR would be stronger among homozygous GSTP1 105 Ile carriers, and wanted to answer this question in a large population-based study.
METHODS

Study population
The SAPALDIA cohort, Swiss Study on Air Pollution And Lung and heart Disease In Adults, a prospective multicenter study, representative of the adult Swiss general population, investigates environmental and genetic factors determining lung health. Ethical approval for the study was given by the central ethics committee of the Swiss Academy of Medical Sciences and the Cantonal Ethics Committees for each of the eight examination areas. Baseline and follow-up examinations eleven years later have previously been described in detail. [18, 19] Briefly, 9561 subjects predominantly of European-Caucasian ethnicity, aged 18-60 years were examined at baseline (1991). 8047 (84%) agreed to participate fully or partly at the follow-up survey (2002) . Information on health and life style was collected by computerassisted personal interview at both time points. Lung function was evaluated using the same spirometer devices (Sensormedics model 2200, Yorba Linda, USA) at both time points. [20] Skin reactivity to eight common airborne allergens was assessed by skin prick test at baseline. Circulating serum levels of total IgE and Phadiatop test for detection of allergen-specific IgE were measured at baseline using the CAP FEIA system (Pharmacia Diagnostics, Uppsala, Sweden). Blood for DNA extraction and informed consent to genetic testing was collected at follow-up.
Methacholine challenge
BHR was assessed by methacholine challenge (Provocholine® , Roche, Nutley, New Jersey, USA) in 7126 participants at baseline. Increasing concentrations of methacholine (0.39, 1.56, 6.25, and 25.0 mg/ml solutions in a phosphate buffer without phenol) were administered through an aerosol dosimeter (Mefar MB3, Bovezzo, Italy). [21] The presence of BHR was defined as a 20% or greater drop in FEV1 up to a cumulative dose of 2mg (8.37µmol ). The methacholine responsiveness was determined for each subject by calculating individual dose-response slopes similar to the method suggested by O'Connor et al. [22, 23] The slope was then defined as the ratio between the percentage decline in FEV1 and the total cumulative dose of methacholine. [18, 19, 25] Former smokers at baseline or follow-up were smokers who had quit smoking at least 1 month before the examination. Current smokers reported active smoking at the interview. The amount of cigarette exposure of participants was assessed by pack-years. Environmental tobacco smoke (ETS) was defined by a positive answer to the question "Have you been regularly exposed to tobacco smoke in the last 12 months? ("regularly" means on most days or nights)?" .
Genotyping
Whole blood was sampled at follow-up and DNA was extracted manually [19] using the Gentra™ Puregene Kit (GENTRA Systems, Minneapolis, USA). Genotyping of the GSTP1 Ile105Val single nucleotide polymorphism and the gene deletion polymorphisms for GSTM1 and GSTT1 was performed by TaqMan® methodology as previously described. [12] Hardy-Weinberg equilibrium (HWE) for the GSTP1 Ile105Val polymorphism was tested using Arlequin Version 2.000 [26] and genotype distribution was found to be in HWE. Genotype frequencies did not differ by Swiss language region or subjects' nationality.
Study sample
We included in the present analysis SAPALDIA participants with valid spirometry and bronchial challenge data from the baseline examination and questionnaire data who participated in the interview at follow-up (n=5825; see supplementary online Figure 1 ). Valid information on respiratory health status at baseline and follow-up as well as genotype information on the GST polymorphisms was available from 4682 of these participants. Subjects who had reported physician-diagnosed asthma at baseline were excluded (n=256). The final sample size for this study consisted of 4426 SAPALDIA participants. Missing information for covariates: baseline FVC (n=105), atopy (n=99), pack-years smoked during follow-up (n=112), ETS exposure (n=5), occupational inhalant exposure (n=332) reduced the study sample available for multiple regression analysis to 3806 subjects of which 3.1% reported for the first time physician-diagnosed asthma at follow-up (n=119).
Statistical analysis
Differences in genotype frequency between cases and controls were assessed by Chi2 test. The associations between GST genotypes and bronchoconstrictor response slope measured as % FEV1 drop per µmol methacholine at baseline were assessed by multiple linear regression adjusting for baseline information on FEV1, FEV1 squared, study area, sex, age, BMI, atopy, smoking status and pack-years smoked; predicted values for GSTP1 Ile105Val genotypes were displayed using the box plot command. The effects of BHR at baseline and GST genotypes on the risk for reporting new physician-diagnosed asthma and current asthma symptoms at follow-up were estimated using multiple logistic regression analysis adjusted for sex, age, study area, baseline measures of FVC and body mass index (BMI), weight change during follow-up, and follow-up information on smoking status, amount of pack-years smoked, ETS and occupational dust, fumes and vapors exposure. Modification of the effect of baseline BHR on incident asthma reports by GSTP1 Ile105Val genotype was assessed by including a multiplicative interaction term in the model, as well as by stratifying analysis by genotype. Cumulative asthma incidences (95% CI) in subgroups defined by combinations of GSTP1 Ile105Val genotypes and baseline BHR were calculated using the adjust command after multivariate logistic regression analysis. Two-sided p-values of <0.05 and <0.10 were considered as statistically significant for main effects and interactions. [27] All analyses were conducted using STATA SE version 9.1 (Stata Corporation, TX, USA).
RESULTS
The characteristics of the study population over all and stratified by the presence or absence of baseline BHR are presented in Table 1 . Among the 4426 participants free of asthma at baseline 3.3% (n=144) reported a history of physician-diagnosed asthma at the follow-up examination.
Fourteen percent of the study sample had BHR at baseline; women were overrepresented in the group exhibiting BHR. Lung function was lower and the proportion of subjects with FEV1/FVC <0.70 higher in the subgroup with BHR. Smokers were more likely to have BHR and the mean amount of pack-years smoked was higher in subjects with BHR, whereas no difference in ETS exposure or occupational exposure to gas, dust, and fumes was noted between the two BHR groups. Baseline respiratory symptoms such as wheezing, chronic cough and phlegm, and shortness of breath at night were more prevalent in the group with BHR; 19.7% of subjects with BHR reported at least one respiratory symptom compared to only 11.5% of participants without BHR. The GST genotype distributions agreed well with those previously reported in other Caucasian populations. [13, 16, 28] Earlier reports suggested that GSTP1 genotype might be associated with BHR. [16] Table  1 shows that the distribution of the various GSTP1 Ile105Val genotypes was not materially different among participants with or without BHR. Homozygous Ile-carriers were slightly underrepresented among subjects with baseline BHR, but the difference did not reach statistical significance (44.6% vs. 47.2%; P=0.23; Table 1 ). We also compared the adjusted methacholine dose response according to GST genotypes ( Figure 1) . No difference in response to the bronchoconstrictor was observed between the three GSTP1 Ile105Val genotypes. GSTM1 and GSTT1 genotypes were not associated with response to methacholine (data not shown). Homozygous GSTP1 Ile/Ile genotypes were slightly overrepresented among subjects with asthma at baseline (p=0.06). Neither GSTM1 nor GSTT1 genotype was associated with self-reported physician-diagnosed asthma at baseline (see supplementary online Table 1 ).
In Table 2 , we present the unadjusted association of both, GST genotypes and baseline BHR with physician-diagnosed asthma at follow-up. Both, baseline BHR and GSTP1 Ile105Val genotype, but not GSTM1 or GSTT1 gene deletion polymorphisms were associated with new asthma reports at follow-up (P<0.001 for baseline BHR and P=0.005 for GSTP1 genotype). The independent associations of baseline BHR and GSTP1 genotype with physician-diagnosed asthma at follow-up were confirmed after adjustment for potential confounders and mutual adjustment for each other (Figure 2 ). The adjusted odds ratio (OR (95% CI)) for BHR vs. no BHR was 3.52 (2.31 -5.35; P<0.001) and for GSTP1 105Ile/Ile vs. GSTP1 105Val genotypes it was 1.71 (1.17 -2.50; P=0.006).
The BHR effect on new reports of asthma and asthma symptoms was modified by GSTP1 ( The adjusted 11-year cumulative incidence of self-reported physician-diagnosed asthma was 14 cases per 1000 persons (95% CI: 9 -21 per 1000) among subjects without baseline BHR and no GSTP1 Ile/Ile genotype; 19 cases (13 -28 per 1000) among subjects without BHR, but with GSTP1 Ile/Ile genotype; 21 cases (9 -45 per 1000) among subjects with BHR and no GSTP1 Ile/Ile genotype; and 95 cases (59 -150 per 1000) among subjects with both, baseline BHR and GSTP1 105Ile/Ile genotype. Thus, among participants with baseline BHR in this study population the excess number of incident asthma cases due to GSTP1 Ile/Ile genotype was 74/1000 persons over the 11-year follow-up period.
Since GST genotypes have previously been associated with lung growth in children [10] and with lung function in adults, [12, 14] we performed a sensitivity analysis and omitted the adjustment for baseline lung function from all statistical models. None of the effects presented were materially altered (data not shown).
DISCUSSION
We present evidence that adults with BHR and GSTP1 Ile/Ile genotype are at an increased risk to develop asthma. Furthermore, genetic variation in GSTP1, but not GSTM1 or GSTT1 modifies the risk of BHR progression to asthma in the general population. As GSTP1 exhibits the highest lung tissue expression of the three GST enzymes, our results are in line with the hypothesis that the extent of local inflammation in the airways contributes to airway remodelling and thus to the association between BHR and adult-onset asthma.
Airway smooth muscle dysfunction [29] [30] [31] and increased airway wall thickening [32, 33] caused by airway remodelling is commonly thought to underlie BHR and possibly its progression to asthma. Prolonged or repeated exposure to airway irritants (i.e. tobacco smoke, ambient air pollution or occupational activity derived particles) can cause airway dysfunction of the smooth muscle and the bronchial epithelium through the induction of chronic airway inflammation. [21, 34, 35] BHR itself contributes to a harmful circle of sustained inflammation, since the associated abnormal airflow resulting from the reduced airway caliber alters the deposition profile of inhalants in the airways. [36] [37] [38] [39] Hence it seems probable that increased depositions of particles with mostly oxidative properties will result in sustained airway inflammation and oxidative stress. This view is corroborated by recent SAPALDIA results showing that BHR increased the effect of ETS exposure on the incidence of asthma-related symptoms. [3, 40] According to our results, the genetic make-up of a person co-determines the exposure load necessary to induce sustained inflammation, oxidative stress, and airway remodelling in the bronchial tissue. The modifying effect of the GSTP1 Ile105Val genotype may reflect the different, but related roles of this enzyme, i.e. in phase II detoxification of tobacco-or air pollution-derived chemicals, [7] in oxidant defense, [41] and in cell cycle regulation. [42] Lower GSTP1 activity in bronchial tissue is likely to result in decreased detoxification of airway irritants, in enhanced inflammation and oxidative stress causing sustained airway wall thickening and smooth muscle dysfunction. This hypothesized pathophysiological mechanism is supported by evidence about the direct involvement of GSTP1 in the regulation of C-JUN N-terminal protein kinase (JNK) and down stream processes, which lead to increased cell proliferation in response to oxidative stress. [43, 44] Mice deficient for GSTP1 activity are prone to increased tumorigenesis upon exposure to polycylic hydrocarbon exposure. [45] The modifying effect of GSTP1 in the BHR/asthma association may therefore result from the central role of this enzyme and oxidative stress in apoptotic processes.
Previous evidence supports the hypothesis that the degree of airway inflammation and oxidative stress contributes to BHR progression. First, in utero exposure to maternal smoking increases the risk of progression from BHR to asthma. [46] Passive smoking has been identified to confer increased oxidative stress locally in bronchial tissue as well as systemically in exposed subjects. [47] [48] [49] Second, obesity characterized by increased systemic inflammation has been associated with increased progression of BHR and asthma. [31] Third, Cheng et al. found a gradient of free radical concentrations in nasal polyps (NP), an inflammatory chronic disease frequently associated with BHR and asthma. Concentrations were lowest in NP cases without BHR and asthma, intermediate in NP cases with concurrent silent BHR, and highest in NP cases with concurrent BHR and asthma. [50] Genetic GST variants have previously been associated with asthma in different, exclusively cross-sectional studies. The prevalence of the GSTP1 105Val allele was lower in patients with asthma, [51, 52] BHR [16] and asthmatics with severe disease. [16, 17, 53, 54] Our findings extend this observation and indicate that the GSTP1 105Ile/Ile genotype, which is carried by about 47% of our European-Caucasian population, represents a prevalent asthma risk factor in the general adult population. The absence of a cross-sectional GSTP1/BHR association in our population-based study contrasts the positive association by Fryer and colleagues [16] . Their study had recruited volunteers and patients from respiratory clinics. Female subjects were overrepresented (>70%). Women are known to be more susceptible to bronchoconstrictor challenge, [16, 23] although in the SAPALDIA cohort the GSTP1/BHR association was not modified by gender (data not shown). Our lacking association of GSTM1 and GSTT1 gene deletion with asthma occurrence also contrasts some previous results. A few small case-control studies suggest that the prevalence of GSTM1 and GSTT1 gene deletions is increased in asthmatics with concurrent atopy. [55, 56] In a limited number of cohorts, GSTM1 and GSTT1 deficiency increased the risk for asthma, asthma-related symptoms and low lung function during childhood in combination with in utero and/or current passive smoking exposure. [10, 11, 57] Protective effects of anti-oxidant supplementation on the lung function of asthmatic children exposed to high ambient ozone were restricted to GSTM1-deficient participants. [58] The discrepancy between our study and previous reports with regard to the role of GSTM1 and GSTT1 deletions might partly be related to differences in study population, sample size, study design, or inhalant exposures. Most importantly, we focused on adult incident asthma, whereas evidence for a GSTM1 or GSTT1/asthma association was most consistently found in children. Unfortunately, our sample size was insufficient to additionally stratify the results by atopy or exposure to environmental inhalants including ETS.
The strength of the present study is its prospective design, which allowed us to investigate long term effects of BHR in the general population. The large sample size of the cohort and its detailed characterization made it possible to investigate the interaction between BHR and GST genotypes on incidence of adult onset asthma. In addition it was possible to refine the analysis after exclusion of participants who might have had asthma symptoms at baseline without the formal diagnosis of asthma. Nevertheless, the number of new asthma cases available to estimate the effect modification of baseline BHR by the GSTP1 genotype was limited. Independent studies thus needed to confirm our novel finding.
The definition of asthma in the present study relied solely on the self-report of asthma phenotypes. Asthma status may therefore be subject to misclassification. [59, 60] The unknown degree of population stratification is another limitation, as no panel of anonymous markers was tested to assay the population admixture of the Swiss general population. But stratification of the associations by study centre, language region, and nationality did not materially alter the main findings, suggesting a minor influence of population stratification at best. We cannot exclude participation bias. Participants at baseline were less likely to be of intermediate age or of Swiss nationality, but were more likely to be former smokers and to report asthma or wheezing than non-participants. [18, 19] Unlike participation at baseline, asthmatics were less likely to participate at followup. [3, 19] Slightly more males, smokers, subjects with low educational background, with occupational exposure to fumes, gas and dust, and with respiratory symptoms were nonparticipants at the follow-up examination. No difference was noted for atopy and BHR between participants and non-participants at follow-up. Subjects with low lung function, a risk factor for BHR, [61] were less likely to undergo methacholine challenge, [3] but we had previously presented results from the SAPALDIA cohort that in contrast to previous evidence [14] GSTP1 was not associated with lung function in this adult sample from the general population. [12] In the absence of genotype information on non-participant at baseline and follow-up we cannot analyze whether we failed to include subjects with unique genotype/phenotype combinations. Even though it is unlikely that genotype status influenced participation, this possible source of bias also points to the need for independent studies to confirm our result.
In conclusion, we present evidence that the GSTP1 Ile/Ile genotype may be a strong and prevalent risk factor for the progression of silent BHR to asthma in the general population. If confirmed by additional studies, the results are consistent with genetic variation in local metabolism of inhalant derived chemicals and/or free radicals playing a relevant role in the progression from BHR to asthma.
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